404 related articles for article (PubMed ID: 23539269)
1. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.
Bjerke L; Mackay A; Nandhabalan M; Burford A; Jury A; Popov S; Bax DA; Carvalho D; Taylor KR; Vinci M; Bajrami I; McGonnell IM; Lord CJ; Reis RM; Hargrave D; Ashworth A; Workman P; Jones C
Cancer Discov; 2013 May; 3(5):512-9. PubMed ID: 23539269
[TBL] [Abstract][Full Text] [Related]
2. G34, another connection between MYCN and a pediatric tumor.
Huang M; Weiss WA
Cancer Discov; 2013 May; 3(5):484-6. PubMed ID: 23658294
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma: histone mutations take the MYCN.
McCarthy N
Nat Rev Cancer; 2013 Jun; 13(6):382-3. PubMed ID: 23615692
[No Abstract] [Full Text] [Related]
4. Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM.
Pathak P; Jha P; Purkait S; Sharma V; Suri V; Sharma MC; Faruq M; Suri A; Sarkar C
J Neurooncol; 2015 Feb; 121(3):489-97. PubMed ID: 25479829
[TBL] [Abstract][Full Text] [Related]
5. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Schwartzentruber J; Korshunov A; Liu XY; Jones DT; Pfaff E; Jacob K; Sturm D; Fontebasso AM; Quang DA; Tönjes M; Hovestadt V; Albrecht S; Kool M; Nantel A; Konermann C; Lindroth A; Jäger N; Rausch T; Ryzhova M; Korbel JO; Hielscher T; Hauser P; Garami M; Klekner A; Bognar L; Ebinger M; Schuhmann MU; Scheurlen W; Pekrun A; Frühwald MC; Roggendorf W; Kramm C; Dürken M; Atkinson J; Lepage P; Montpetit A; Zakrzewska M; Zakrzewski K; Liberski PP; Dong Z; Siegel P; Kulozik AE; Zapatka M; Guha A; Malkin D; Felsberg J; Reifenberger G; von Deimling A; Ichimura K; Collins VP; Witt H; Milde T; Witt O; Zhang C; Castelo-Branco P; Lichter P; Faury D; Tabori U; Plass C; Majewski J; Pfister SM; Jabado N
Nature; 2012 Jan; 482(7384):226-31. PubMed ID: 22286061
[TBL] [Abstract][Full Text] [Related]
6. Cerebral hemispheric glioblastoma with PNET-like morphology and histone H3.3 G34 mutation in younger patients: Report of three rare cases and diagnostic pitfalls.
Cheng Y; Bao W; Wu Q
Indian J Pathol Microbiol; 2020; 63(2):262-266. PubMed ID: 32317528
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR
Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300
[TBL] [Abstract][Full Text] [Related]
8. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Sturm D; Witt H; Hovestadt V; Khuong-Quang DA; Jones DT; Konermann C; Pfaff E; Tönjes M; Sill M; Bender S; Kool M; Zapatka M; Becker N; Zucknick M; Hielscher T; Liu XY; Fontebasso AM; Ryzhova M; Albrecht S; Jacob K; Wolter M; Ebinger M; Schuhmann MU; van Meter T; Frühwald MC; Hauch H; Pekrun A; Radlwimmer B; Niehues T; von Komorowski G; Dürken M; Kulozik AE; Madden J; Donson A; Foreman NK; Drissi R; Fouladi M; Scheurlen W; von Deimling A; Monoranu C; Roggendorf W; Herold-Mende C; Unterberg A; Kramm CM; Felsberg J; Hartmann C; Wiestler B; Wick W; Milde T; Witt O; Lindroth AM; Schwartzentruber J; Faury D; Fleming A; Zakrzewska M; Liberski PP; Zakrzewski K; Hauser P; Garami M; Klekner A; Bognar L; Morrissy S; Cavalli F; Taylor MD; van Sluis P; Koster J; Versteeg R; Volckmann R; Mikkelsen T; Aldape K; Reifenberger G; Collins VP; Majewski J; Korshunov A; Lichter P; Plass C; Jabado N; Pfister SM
Cancer Cell; 2012 Oct; 22(4):425-37. PubMed ID: 23079654
[TBL] [Abstract][Full Text] [Related]
9. Effects of H3.3G34V mutation on genomic H3K36 and H3K27 methylation patterns in isogenic pediatric glioma cells.
Huang TY; Piunti A; Qi J; Morgan M; Bartom E; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2020 Dec; 8(1):219. PubMed ID: 33287886
[TBL] [Abstract][Full Text] [Related]
10. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin.
Gallo M; Coutinho FJ; Vanner RJ; Gayden T; Mack SC; Murison A; Remke M; Li R; Takayama N; Desai K; Lee L; Lan X; Park NI; Barsyte-Lovejoy D; Smil D; Sturm D; Kushida MM; Head R; Cusimano MD; Bernstein M; Clarke ID; Dick JE; Pfister SM; Rich JN; Arrowsmith CH; Taylor MD; Jabado N; Bazett-Jones DP; Lupien M; Dirks PB
Cancer Cell; 2015 Dec; 28(6):715-729. PubMed ID: 26626085
[TBL] [Abstract][Full Text] [Related]
11. Histone H3.3 G34 Mutations Alter Histone H3K36 and H3K27 Methylation In Cis.
Shi L; Shi J; Shi X; Li W; Wen H
J Mol Biol; 2018 May; 430(11):1562-1565. PubMed ID: 29689253
[TBL] [Abstract][Full Text] [Related]
12. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?
Chan KM; Han J; Fang D; Gan H; Zhang Z
Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119
[TBL] [Abstract][Full Text] [Related]
13. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity.
Korshunov A; Capper D; Reuss D; Schrimpf D; Ryzhova M; Hovestadt V; Sturm D; Meyer J; Jones C; Zheludkova O; Kumirova E; Golanov A; Kool M; Schüller U; Mittelbronn M; Hasselblatt M; Schittenhelm J; Reifenberger G; Herold-Mende C; Lichter P; von Deimling A; Pfister SM; Jones DT
Acta Neuropathol; 2016 Jan; 131(1):137-46. PubMed ID: 26482474
[TBL] [Abstract][Full Text] [Related]
14. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
[TBL] [Abstract][Full Text] [Related]
15. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers.
Korshunov A; Schrimpf D; Ryzhova M; Sturm D; Chavez L; Hovestadt V; Sharma T; Habel A; Burford A; Jones C; Zheludkova O; Kumirova E; Kramm CM; Golanov A; Capper D; von Deimling A; Pfister SM; Jones DTW
Acta Neuropathol; 2017 Sep; 134(3):507-516. PubMed ID: 28401334
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C
Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139
[TBL] [Abstract][Full Text] [Related]
17. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
18. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
19. Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
Murphy DM; Buckley PG; Das S; Watters KM; Bryan K; Stallings RL
PLoS One; 2011; 6(6):e21436. PubMed ID: 21731748
[TBL] [Abstract][Full Text] [Related]
20. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
